Reata Pharmaceuticals Stock Analysis

Find the latest reata pharmaceuticals, inc. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

Reata Stock Reta Big Run-up Toward Approval Seeking Alpha

The stock has a consensus analyst rating of buy. a buy rating indicates that analysts believe reta will outperform the market and that investors should add to their positions of reata pharmaceuticals.

Reata pharmaceuticals stock analysis. (reta) stock, including valuation metrics, financial numbers, share information and more. Earnings and valuation of reata pharmaceuticals (nasdaq:reta. Since then, reta stock has decreased by 48.4% and is now trading at $81.46.

Cl a analyst estimates, including reta earnings per share estimates and analyst recommendations. Detailed financial statements for reata pharmaceuticals, inc. (reta) stock chart with full price history, volume, trends and moving averages.

Ad unparalleled coverage & analytic comparison. Exclusive research and insights from bulls and bears. (reta) saw an uptrend of 3.62% in the recent trading with $110.96 being its most recent.

Try our software for free today. View the latest ratings for reta. (reta), including the income statement, balance sheet, and cash flow statement.

Detailed statistics for reata pharmaceuticals, inc. Only 31.70% of the stock of reata pharmaceuticals is held by insiders. (reta) stock analyst estimates, including earnings and revenue, eps, upgrades and downgrades.

High institutional ownership can be a signal of strong market trust in this company. Ad unparalleled coverage & analytic comparison. Reata pharmaceuticals currently has 3 buy ratings from wall street analysts.

Try our software for free today. Class a common stock (reta) nasdaq listed. 64.30% of the stock of reata pharmaceuticals is held by institutions.

The company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or. Earnings for reata pharmaceuticals are expected to. Bardoxolone methyl, omaveloxolone, and rta 901 are.

**subject to discussion with regulatory authorities. Cl a stock information by barron's. According to the issued ratings of 3 analysts in the last year, the consensus rating for reata pharmaceuticals stock is buy based on the current 3 buy ratings for reta.

Data is currently not available. (reta) stock analysis from seeking alpha’s top analysts: *nda accepted for filing by the fda;

The company is developing phase iii clinical trial programs, including bardoxolone methyl (bardoxolone.